High scar burden on CMR, higher B‐type natriuretic peptide level and lower LVEF at the initial LVEF recovery have been demonstrated as independent predictors of a relapse in cardiac dysfunction in patients with DCM26; factors that are again less common in patients with breast cancer and HER2 CTRCD. This evidence concerns the gene ERBB2 and breast cancer.